8-KLeadership ChangesMaterial AgreementsRegulation FD+1

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Sep 19, 2016)

Filed September 19, 2016For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on September 19, 2016, primarily to announce a significant executive appointment and the entry into new indemnification agreements. The key event is the appointment of Yvonne Greenstreet as Executive Vice President, Chief Operating Officer. Dr. Greenstreet brings substantial experience from Pfizer and GlaxoSmithKline, and her role is expected to contribute to the company's strategic development and market execution. In connection with her appointment, Dr. Greenstreet will receive a competitive compensation package, including a base salary, sign-on bonus, eligibility for annual bonuses, and a substantial stock option grant. The stock options have specific vesting conditions tied to time and the potential launch of a company product, aligning her incentives with long-term company success. The filing also confirms the entry into standard indemnification agreements for all current directors and executive officers, designed to provide maximum legal protection and supplement existing provisions.

Key Highlights

  • 1Appointment of Yvonne Greenstreet, MBChB, MBA, as Executive Vice President, Chief Operating Officer, effective September 19, 2016.
  • 2Dr. Greenstreet possesses extensive prior experience at major pharmaceutical companies including Pfizer and GlaxoSmithKline, as well as entrepreneurial experience.
  • 3Dr. Greenstreet's compensation package includes a $500,000 annual base salary and a $100,000 sign-on bonus.
  • 4She is eligible for an annual cash bonus with a target of 50% of her base salary, subject to performance goals.
  • 5A significant stock option grant of 150,000 shares was awarded to Dr. Greenstreet as an inducement for joining the company, with a portion tied to product launch.
  • 6The company entered into indemnification agreements with all current directors and executive officers, enhancing their legal protections.
  • 7The appointment and related compensation details were communicated via a press release furnished as an exhibit.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce the appointment of Yvonne Greenstreet as the new Chief Operating Officer of Alnylam Pharmaceuticals, Inc., and to detail her compensation package. It also formally reports the entry into new indemnification agreements with the company's directors and officers.

Dr. Greenstreet has a strong background in the pharmaceutical industry, having held senior leadership positions at Pfizer and GlaxoSmithKline, focusing on medicines development and strategy. She also founded a consulting firm in the life sciences sector. Her experience is expected to be valuable in driving Alnylam's business strategies and bringing its products to market.

Dr. Greenstreet's compensation includes an annual base salary of $500,000, a $100,000 sign-on bonus (which is repayable under certain conditions within the first year), eligibility for an annual cash bonus targeting 50% of her base salary, and a grant of 150,000 stock options with a strike price of $77.10. She is also eligible for relocation expenses and other standard executive benefits.

The stock option grant is intended as a material inducement for Dr. Greenstreet to join Alnylam, in compliance with NASDAQ rules. The grant includes performance-based vesting for a portion of the options, contingent on the launch of the company's first internally developed product, which aligns her long-term incentives with the company's strategic milestones and shareholder value.